Blog

Enrolling patients in clinical trials has long been one of the steepest operational hurdles in medical innovation. For years, researchers have debated whether financial compensation serves as a necessary driver for recruitment or an unethical bribe that skews participant motivation. A recent study published in JAMA Internal Medicine provides crucial clarity on this long-standing dilemma. The data reveals … Read more

When senior FDA leadership published “America Must Address Early Clinical Development” on the official FDA Voices blog, industry stakeholders immediately take notice. However, beneath the bold rhetoric lies a familiar structural tension that has plagued recent regulatory communications: the conflation of executive vision with enforceable policy. Outlining an ambitious “Expedited IND Pilot” utilizing Qualified Research Institutions (QRIs) and rolling submissions, the agency framed the … Read more

Imagine the sinking feeling of receiving a notification from your customs broker that your multi-million-dollar food shipment is officially detained at the port. You have buyers waiting on scheduled store delivery windows, warehousing demurrage charges piling up daily, and perishable goods slowly losing market value in a shipping container. For hundreds of U.S. food importers … Read more

For decades, rigid and boilerplate eligibility criteria have turned cancer clinical trials into exclusive clubs, leaving vast segments of real-world patients stranded on the outside. By routinely excluding individuals with minor laboratory anomalies, mild performance deficits, or complex medication regimens, trial sponsors have inadvertently compromised both subject accrual and the generalizability of study results. Recognizing … Read more

Navigating the regulatory clearance process for high-risk medical devices within the Center for Biologics Evaluation and Research (CBER) extends beyond securing an approval or denial order. Once a decision is rendered, regulatory affairs professionals must oversee the post-action administrative workflows that dictate public transparency. CBER’s Standard Operating Policy and Procedure (SOPP) 8795 establishes the internal mechanisms governing public … Read more

Financial conflict of interest in medical research is a topic that instantly draws headlines, skepticism, and heated academic debates. A recent study published in JAMA Network Open reignited this fire by pointing out that nearly 90% of industry-funded trials report conclusions favoring their corporate sponsors. To many observers, that statistic sounds like smoking-gun evidence that commercial money corrupts scientific … Read more

Bringing a molecule like psilocybin or MDMA to the commercial market is unlike any traditional drug development journey. In its guidance document, the FDA is proving a long-awaited regulatory map to describe how developing these drugs mirrors conventional drug development, and where it chart-starts entirely new territory. At their core, psychedelic drug programs are not exempt from the golden standards of modern medicine. The FDA makes it clear that … Read more

Navigating the labyrinth of FDA regulations often feels like learning a highly specialized dialect of a language you only half-understand. With the release of the July 2026 guidance on formal meetings for Over-the-Counter (OTC) monograph drugs, the agency has introduced a brand-new vocabulary of Type X, Y, and Z meetings. While these terms might sound like characters in an … Read more

Have you ever sent a quick note to your doctor through a patient portal and wondered about the voice on the other side? As healthcare digital infrastructure expands, the overwhelming volume of incoming messages is driving massive clinician burnout. In response, health systems are rapidly turning to generative artificial intelligence (AI) to draft replies. But how … Read more

The commercial development of genome-edited (GE) human gene therapies has historically been constrained by the regulatory mandate to treat every single therapeutic asset as an entirely blank slate. This rigid paradigm frequently forced sponsors to expend millions of dollars and precious clinical timelines executing redundant validation and nonclinical testing protocols for highly related platform technologies. However, the FDA’s latest guidance represents a watershed … Read more